Skip to Content

Tools

Report

Effectiveness of National Biosurveillance Systems: BioWatch and the Public Health System. Interim Report

Released:
February 6, 2009
Type:
Consensus Report
Topics:
Diseases, Public Health
Activity:
Effectiveness of National Biosurveillance Systems: BioWatch and the Public Health System
Board:
Board on Health Sciences Policy

For many years, concerns about bioterrorism and emerging infectious diseases have drawn attention to the need for strong surveillance systems. Experts are working to develop new and better ways to detect these biological threats as quickly as possible so that appropriate action can minimize illnesses and deaths. One effort in this area is the Department of Homeland Security's BioWatch program, through which air samples collected in more than 30 major localities are tested for the presence of certain pathogens.

To evaluate the effectiveness of the BioWatch program, the Institute of Medicine (IOM) and National Research Council (NRC) convened the Committee on Effectiveness of National Biosurveillance Systems: BioWatch and the Public Health System. The evaluation includes a comparison of costs and benefits for the current generation and planned next generation of BioWatch technology; the costs and benefits of an enhanced national surveillance system that relies on U.S. hospitals and the U.S. public health system; and the effectiveness of this approach compared to that of the current BioWatch program.

This interim report contains no findings and recommendations, but outlines the committee's initial progress in addressing the major issues under consideration.


Other Reports by this Activity

  • BioWatch and Public Health Surveillance: Evaluating Systems for the Early Detection of Biological Threats. Abbreviated Version: Summary In 2003, the Department of Homeland Security (DHS) introduced the BioWatch program—a federal monitoring system intended to speed detection of specific biological agents that could be released in aerosolized form during a biological attack. A report by the IOM and the National Research Council evaluates the costs and merits of the BioWatch program, examines infectious disease surveillance through U.S. hospitals and public health agencies, and considers whether BioWatch and traditional infectious disease surveillance are redundant or complementary.
    Released: December 7, 2009

Get this Report

Stay up to date!